Lena Specht mostly deals with Radiation therapy, Nuclear medicine, Internal medicine, Oncology and Surgery. Lena Specht combines subjects such as Stage, Breast cancer and Lymphoma, Hodgkin's lymphoma with her study of Radiation therapy. Her Stage research is multidisciplinary, incorporating elements of BEACOPP and Chemotherapy.
Her Nuclear medicine research incorporates elements of ABVD, Lung, Breathing and Dacarbazine. Her Oncology research incorporates themes from Odds ratio, Randomized controlled trial, Risk factor and Hazard ratio. Her Surgery study combines topics from a wide range of disciplines, such as Univariate analysis and Standard treatment.
Lena Specht mainly focuses on Radiation therapy, Internal medicine, Oncology, Radiology and Nuclear medicine. Her Radiation therapy research includes themes of Stage, Disease, Chemotherapy and Lymphoma. Internal medicine is closely attributed to Gastroenterology in her study.
In general Oncology study, her work on Chemotherapy regimen often relates to the realm of In patient, thereby connecting several areas of interest. While the research belongs to areas of Radiology, Lena Specht spends her time largely on the problem of Lung cancer, intersecting her research to questions surrounding Locally advanced. Her study in Nuclear medicine is interdisciplinary in nature, drawing from both Breast cancer, Planning target volume, Lung and Computed tomography.
The scientist’s investigation covers issues in Internal medicine, Radiation therapy, Oncology, Lymphoma and Radiology. Her biological study spans a wide range of topics, including Deep inspiration breath-hold, Lung cancer, Nuclear medicine and Stage. Her work in the fields of Positron emission tomography overlaps with other areas such as Image quality.
Her work in the fields of Oncology, such as Progression-free survival, intersects with other areas such as In patient. Her studies deal with areas such as Survival analysis and Population based study as well as Progression-free survival. Her Lymphoma research focuses on Leukemia and how it connects with Bone marrow.
Her scientific interests lie mostly in Internal medicine, Radiation therapy, Oncology, Nuclear medicine and Lymphoma. Her Radiation therapy research is under the purview of Radiology. The study incorporates disciplines such as Hematopoietic stem cell transplantation, Refractory, Salvage therapy, Chemotherapy and Hazard ratio in addition to Oncology.
Lena Specht interconnects Vinblastine, Effective diffusion coefficient, Dacarbazine and Hounsfield scale in the investigation of issues within Nuclear medicine. Her Lymphoma study incorporates themes from Chemotherapy regimen, Proton therapy, Radiation oncology, Disease and Leukemia. Her biological study deals with issues like Hodgkin lymphoma, which deal with fields such as Stage.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Revised response criteria for malignant lymphoma
Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne.
Journal of Clinical Oncology (2007)
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
Andrea Gallamini;Martin Hutchings;Luigi Rigacci;Lena Specht.
Journal of Clinical Oncology (2007)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Martin Hutchings;Annika Loft;Annika Loft;Mads Hansen;Mads Hansen;Lars Møller Pedersen;Lars Møller Pedersen.
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
Jens Overgaard;Hanne Sand Hansen;Lena Specht;Marie Overgaard.
The Lancet (2003)
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
Jens Overgaard;Hanne Sand Hansen;Marie Overgaard;Lars Bastholt.
Radiotherapy and Oncology (1998)
Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis
Padraig Warde;Lena Specht;Alan Horwich;Tim Oliver.
Journal of Clinical Oncology (2002)
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Lena Specht;Joachim Yahalom;Tim Illidge;Anne Kiil Berthelsen.
International Journal of Radiation Oncology Biology Physics (2014)
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
Theodore Girinsky;Richard van der Maazen;Lena Specht;Berthe Aleman.
Radiotherapy and Oncology (2006)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre;Theodore Girinsky;Massimo Federico;Oumedaly Reman.
Journal of Clinical Oncology (2017)
Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation.
Jens Jørgen Thorn;Hanne Sand Hansen;Lena Specht;Lars Bastholt.
Journal of Oral and Maxillofacial Surgery (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: